{"entity":{"id":"nct05125016","kind":"trial","name":"A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer","aka":[],"tldr":"A phase 1/2 trial of REGN4336 in prostate cancer, run by Regeneron Pharmaceuticals, now recruiting.","summary":"A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer is a phase 1/2 interventional study registered as NCT05125016 by Regeneron Pharmaceuticals, with 228 participants planned, started 2021-11-30 and due to reach its primary completion in 2030-03-28. Interventions recorded: REGN4336 and REGN5678.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05125016","url":"https://clinicaltrials.gov/study/NCT05125016"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["regeneron"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05125016","phase":"1/2","setting":"Phase 1/2 Study of REGN4336 (a PSMAxCD3 Bispecific Antibody) Administered Alone or in Combination With REGN5678 (a PSMAxCD28 Bispecific Antibody) in Patients With Metastatic Castration-Resistant Prostate Cancer","sponsor":"Regeneron Pharmaceuticals","enrolled":228,"outcomes":[]},"route":"/trials/nct05125016/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"company":[{"id":"regeneron","kind":"company","name":"Regeneron","route":"/companies/regeneron/"}]}}